Peer-reviewed veterinary case report
Peptide from alpha fetoprotein stops growth of ER-positive dog
By Torres, Cristian Gabriel et al.·Published in Oncology reports·2009·Laboratorios de Nutrició·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A cyclized peptide derived from alpha fetoprotein inhibits the proliferation of ER-positive canine mammary cancer cells.
- Species:
- dog
Plain-English summary
A group of dogs with mammary tumors, specifically those that were estrogen receptor-positive, were studied to see how a special peptide derived from alpha-fetoprotein (cP) could affect their cancer cells. While the hormone estradiol increased the growth of these cancer cells, the peptide cP was able to stop this growth and even reverse some of the changes caused by estradiol. This suggests that cP could be a promising new treatment option for managing mammary cancer in dogs.
People also search for: dog mammary cancer treatment · canine cancer peptide therapy · estrogen receptor-positive dog tumors
Abstract
The effects of estradiol (E2) and of an AFP-derived cyclized peptide (cP) on the proliferation of primary cultures of cancer cells isolated from spontaneous canine mammary tumors were studied. The cellular response to E2 and cP was related to the expression of estradiol receptor (isoforms alpha and beta). In ER-positive cells, 2 nM estradiol increased cell proliferation and the phosphorylation of ERK1/2; 2 microg/ml cP inhibited all these effects. Estradiol also increased HER2 immunoreactivity in ER-positive cells, an effect that was reverted to its basal values by cP. Estradiol stimulated in these cells the release of MMP2 and MMP9 and the shedding of HB-EGF, effects that the cP did not affect. ER-negative cells were refractory to estradiol or cP. All canine mammary tumor cells in culture responded to treatments analogously to human mammary cancer cells. Our results support the proposal of cP as a new, potentially effective therapeutic agent for the management of mammary cancer.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19424616/